The mitochondrial ATPase6 gene is more susceptible to mutation than the ATPase8 gene in breast cancer patients

Table 4 MtDNA alterations and clinico-pathological characteristics of breast cancer patients with more than one missense mutation

Case	Locus	Variant	Frequency	Age (Yrs)	Grade	Tumor size (cm)	TNM*	Stage
BC-6	ATPase6	A8384G	4	44	III	3	T2N1M0	II
	ATPase6	T8542C
	ATPase8	T8542C
	ATPase8	A8860G
BC-10	ATPase6	A8860G	3	55	III	2.5	T2N0M1	IV
		G8950A
		A9041G
BC-19	ATPase6	A8860G	2	42	II	5	T3N2M1	IV
BC-19	ATPase6	G9055A	2	42	II	5	T3N2M1	IV
BC-20	ATPase6	A8860G	2	68	III	1.8	T2N1M1	IV
BC-20	ATPase6	A9007G	2	68	III	1.8	T2N1M1	IV
BC-21	ATPase6	A8860G	2	43		1.2	T1NXM1	IV
BC-21	ATPase6	G8950A	2	43		1.2	T1NXM1	IV
BC-23	ATPase6	A8860G	2	36	III	10	T3N3M1	IV
BC-23	ATPase6	G9055A	2	36	III	10	T3N3M1	IV
BC-25	ATPase6	A8860G	2	50	II	13	T4N3M1	IV
BC-25	ATPase6	C8794T	2	50	II	13	T4N3M1	IV
BC-32	ATPase6	A8860G	2	74	I	5	T3N1M1	IV
BC-32	ATPase6	T8881C	2	74	I	5	T3N1M1	IV
BC-35	ATPase6	C8794T	2	75	II	5	T3N3M1	IV
BC-35	ATPase6	A8860G	2	75	II	5	T3N3M1	IV
BC-37	ATPase6	A8860G	2	67	II	2	T1N0M0	I
BC-37	ATPase6	G9095A	2	67	II	2	T1N0M0	I
BC-38	ATPase6	A8701G	3	69	II	3.5	T2N3M1	IV
		A8860G
		T9085C
BC-39	ATPase6	A8701G	2	59	III	3	T2N0M0	II
BC-39	ATPase6	A8860G	2	59	III	3	T2N0M0	II
BC-41	ATPase6	C8684T	2	51	II	3.5	T2N0M1	IV
BC-41	ATPase6	A8860G	2	51	II	3.5	T2N0M1	IV
BC-48	ATPase6	T8567C	3	41	II	4.5	T2N3M1	IV
	ATPase8	T8567C
		A8860G

T1–T4: Size and/or extent of the primary tumor; NX: Regional lymph nodes cannot be evaluated; N0: No regional lymph node involvement (no cancer found in the lymph nodes); N1-N3:Involvement of regional lymph nodes (number and/or extent of spread); M0:No distant metastasis; M1:Distant metastasis (spread of cancer from one part of the body to another). There was no significant association between the mtDNA alterations and clinic-pathological characteristics of breast cancer patients.

ISSN: 1475-2867